Kinome-level screening identifies inhibition of polo-like kinase-1 (PLK1) as a target for enhancing non-viral transgene expression

Matthew D. Christensen, Jacob J. Elmer, Seron Eaton, Laura Gonzalez-Malerva, Joshua LaBaer, Kaushal Rege

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Human cells contain hundreds of kinase enzymes that regulate several cellular processes, which likely include transgene delivery and expression. We identified several kinases that influence gene delivery and/or expression by performing a kinome-level screen in which, we identified small-molecule kinase inhibitors that significantly enhanced non-viral (polymer-mediated) transgene (luciferase) expression in cancer cells. The strongest enhancement was observed with several small-molecule inhibitors of Polo-like Kinase 1 (PLK 1) (e.g., HMN-214 and BI 2536), which enhanced luciferase expression up to 30-fold by arresting cells in the G2/M phase of the cell cycle and influencing intracellular trafficking of plasmid DNA. Knockdown of PLK 1 using an shRNA-expressing lentivirus further confirmed the enhancement of polymer-mediated transgene expression. In addition, pairwise and three-way combinations of PLK1 inhibitors with the histone deacetylase-1 (HDAC-1) inhibitor Entinostat and the JAK/STAT inhibitor AG-490 enhanced luciferase expression to levels significantly higher than individual drug treatments acting alone. These findings indicate that inhibition of specific intracellular kinases (e.g., PLK1) can significantly enhance non-viral transgene expression for applications in biotechnology and medicine.

Original languageEnglish (US)
Pages (from-to)20-29
Number of pages10
JournalJournal of Controlled Release
Volume204
DOIs
StatePublished - Apr 28 2015

Fingerprint

Transgenes
Phosphotransferases
Luciferases
Polymers
Histone Deacetylase 1
Lentivirus
Histone Deacetylase Inhibitors
G2 Phase
Biotechnology
Cell Division
Small Interfering RNA
Cell Cycle
Plasmids
Medicine
polo-like kinase 1
DNA
Enzymes
Pharmaceutical Preparations
Genes
Neoplasms

Keywords

  • BI 2536
  • Cell cycle
  • HMN-214
  • Kinases
  • Polymer Gene Delivery
  • Transient protein expression

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Kinome-level screening identifies inhibition of polo-like kinase-1 (PLK1) as a target for enhancing non-viral transgene expression. / Christensen, Matthew D.; Elmer, Jacob J.; Eaton, Seron; Gonzalez-Malerva, Laura; LaBaer, Joshua; Rege, Kaushal.

In: Journal of Controlled Release, Vol. 204, 28.04.2015, p. 20-29.

Research output: Contribution to journalArticle

@article{f83f81e59f754d0d9ad94477bd994fcd,
title = "Kinome-level screening identifies inhibition of polo-like kinase-1 (PLK1) as a target for enhancing non-viral transgene expression",
abstract = "Human cells contain hundreds of kinase enzymes that regulate several cellular processes, which likely include transgene delivery and expression. We identified several kinases that influence gene delivery and/or expression by performing a kinome-level screen in which, we identified small-molecule kinase inhibitors that significantly enhanced non-viral (polymer-mediated) transgene (luciferase) expression in cancer cells. The strongest enhancement was observed with several small-molecule inhibitors of Polo-like Kinase 1 (PLK 1) (e.g., HMN-214 and BI 2536), which enhanced luciferase expression up to 30-fold by arresting cells in the G2/M phase of the cell cycle and influencing intracellular trafficking of plasmid DNA. Knockdown of PLK 1 using an shRNA-expressing lentivirus further confirmed the enhancement of polymer-mediated transgene expression. In addition, pairwise and three-way combinations of PLK1 inhibitors with the histone deacetylase-1 (HDAC-1) inhibitor Entinostat and the JAK/STAT inhibitor AG-490 enhanced luciferase expression to levels significantly higher than individual drug treatments acting alone. These findings indicate that inhibition of specific intracellular kinases (e.g., PLK1) can significantly enhance non-viral transgene expression for applications in biotechnology and medicine.",
keywords = "BI 2536, Cell cycle, HMN-214, Kinases, Polymer Gene Delivery, Transient protein expression",
author = "Christensen, {Matthew D.} and Elmer, {Jacob J.} and Seron Eaton and Laura Gonzalez-Malerva and Joshua LaBaer and Kaushal Rege",
year = "2015",
month = "4",
day = "28",
doi = "10.1016/j.jconrel.2015.01.036",
language = "English (US)",
volume = "204",
pages = "20--29",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - Kinome-level screening identifies inhibition of polo-like kinase-1 (PLK1) as a target for enhancing non-viral transgene expression

AU - Christensen, Matthew D.

AU - Elmer, Jacob J.

AU - Eaton, Seron

AU - Gonzalez-Malerva, Laura

AU - LaBaer, Joshua

AU - Rege, Kaushal

PY - 2015/4/28

Y1 - 2015/4/28

N2 - Human cells contain hundreds of kinase enzymes that regulate several cellular processes, which likely include transgene delivery and expression. We identified several kinases that influence gene delivery and/or expression by performing a kinome-level screen in which, we identified small-molecule kinase inhibitors that significantly enhanced non-viral (polymer-mediated) transgene (luciferase) expression in cancer cells. The strongest enhancement was observed with several small-molecule inhibitors of Polo-like Kinase 1 (PLK 1) (e.g., HMN-214 and BI 2536), which enhanced luciferase expression up to 30-fold by arresting cells in the G2/M phase of the cell cycle and influencing intracellular trafficking of plasmid DNA. Knockdown of PLK 1 using an shRNA-expressing lentivirus further confirmed the enhancement of polymer-mediated transgene expression. In addition, pairwise and three-way combinations of PLK1 inhibitors with the histone deacetylase-1 (HDAC-1) inhibitor Entinostat and the JAK/STAT inhibitor AG-490 enhanced luciferase expression to levels significantly higher than individual drug treatments acting alone. These findings indicate that inhibition of specific intracellular kinases (e.g., PLK1) can significantly enhance non-viral transgene expression for applications in biotechnology and medicine.

AB - Human cells contain hundreds of kinase enzymes that regulate several cellular processes, which likely include transgene delivery and expression. We identified several kinases that influence gene delivery and/or expression by performing a kinome-level screen in which, we identified small-molecule kinase inhibitors that significantly enhanced non-viral (polymer-mediated) transgene (luciferase) expression in cancer cells. The strongest enhancement was observed with several small-molecule inhibitors of Polo-like Kinase 1 (PLK 1) (e.g., HMN-214 and BI 2536), which enhanced luciferase expression up to 30-fold by arresting cells in the G2/M phase of the cell cycle and influencing intracellular trafficking of plasmid DNA. Knockdown of PLK 1 using an shRNA-expressing lentivirus further confirmed the enhancement of polymer-mediated transgene expression. In addition, pairwise and three-way combinations of PLK1 inhibitors with the histone deacetylase-1 (HDAC-1) inhibitor Entinostat and the JAK/STAT inhibitor AG-490 enhanced luciferase expression to levels significantly higher than individual drug treatments acting alone. These findings indicate that inhibition of specific intracellular kinases (e.g., PLK1) can significantly enhance non-viral transgene expression for applications in biotechnology and medicine.

KW - BI 2536

KW - Cell cycle

KW - HMN-214

KW - Kinases

KW - Polymer Gene Delivery

KW - Transient protein expression

UR - http://www.scopus.com/inward/record.url?scp=84924171979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924171979&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2015.01.036

DO - 10.1016/j.jconrel.2015.01.036

M3 - Article

C2 - 25681050

AN - SCOPUS:84924171979

VL - 204

SP - 20

EP - 29

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -